13:00
14:00
15:00
16:00
17:00
18:00
19:00
20:00
21:00
22:00
10 SEPTEMBER 2017
10 SEPTEMBER 2017
SATELLITE SYMPOSIUM organized by the PREPARE consortium
13:15 - 14:45
An integrated approach to understanding influenza
TITLE An integrated approach to understanding influenza
Time
13:15 - 14:45
Location
Omega
Chairs: Peter Openshaw and Menno de Jong
Introduction to the PREPARE consortium
Menno de Jong, University of Amsterdam, The Netherlands
MOSAIC: a multicentre prospective study of severe influenza
Long Hoang, Imperial College London, UK
Influenza H1N1pdm infection of healthy volunteers
Chris Chiu, Imperial College London, UK
Transcriptomics in PREPARE
Cosimo Cristella, University of Amsterdam, The Netherlands
Is flu a disease of immune failure or excess?
Peter Openshaw, Imperial College London, UK

SATELLITE SYMPOSIUM supported by Vaccines Europe and ESWI
15:00 - 16:30
EU manifesto on influenza vaccination
EU manifesto on influenza vaccination
15:00 - 16:30
Location
Omega
Chair: Andrew Harrison
Hanover Communications
1. Roman Prymula
University Hospital Hradec Kralove, Czech Republic
2. Erin Sparrow
Health Systems and Innovation, WHO, Geneva
3. Peter Openshaw
Imperial College London, UK
4. Ted van Essen
University Medical Centre, Utrecht, the Netherlands
5. Isabel Jacinto
National Association of Pharmacies, Lisbon, Portugal

Despite the 2009 Council Recommendation that seasonal influenza vaccination rates should be improved for the elderly, at risk groups and health care workers, there remains a concerning sub-optimal level of influenza vaccination coverage across Europe with 15,000-70,000 people dying each year due to influenza. These worrying facts led to the creation of a multi-stakeholder Steering Group on Influenza Vaccination, whose members are committed to raising awareness of influenza-related public health issues and encouraging stronger policy driven actions at European and national level in support of influenza vaccination. One of the Steering Group's tasks is to draft an EU Manifesto on Influenza Vaccination, a tangible means of aligning the community on the shared policy requirements to protect European citizens from influenza. The idea of developing a Manifesto will be presented during this satellite symposium. Participants will be invited to give their input to this initiative either during the symposium or in advance via an online survey.

SATELLITE SYMPOSIUM organized by ESPID and ESWI, with an unrestricted grant by AstraZeneca
16:45 - 18:15
Should children be vaccinated against influenza?
Should children be vaccinated against influenza?
16:45 - 18:15
Location
Omega
Chairs: Ab Osterhaus and Terho Heikkinen
1. The burden of disease in children
Pieter Fraaij, Erasmus MC Rotterdam, The Netherlands
2. Influenza vaccines for children: how effective are they?
Ab Osterhaus, ESWI chair
3. Universal vaccination of children: experiences from the UK
Richard Pebody, Public Health England, UK
4. Universal vaccination of children: the Finnish approach
Terho Heikkinen, University of Turku, Finland
5. Should children be routinely vaccinated against influenza and how can we foster the implementation of vaccination recommendations?
Panel discussion and audience debate

OPENING CEREMONY
18:30 - 19:30
Location
Omega
Welcome and opening
Ab Osterhaus, ESWI conference chair
Plenary address: Influenza vaccination as a key public health tool
Vytenis Andriukaitis, EU Commissioner Health and Food Safety
Keynote lecture: A universal influenza virus vaccine
Peter Palese, Mount Sinai School of Medicine, USA

WELCOME RECEPTION
19:30 - 22:00
19:30 - 22:00
Location
Main conference hall

 

08:30
09:00
09:30
10:00
10:30
11:00
11:30
12:00
12:30
13:00
13:30
14:00
14:30
15:00
15:30
16:00
16:30
17:00
17:30
18:00
18:30
19:00
19:30
11 SEPTEMBER 2017
11 SEPTEMBER 2017
PLENARY SESSION - keynote lectures
08:30 - 10:00
08:30 - 10:00
Location
Omega
Chair: Terho Heikkinen
University of Turku, Finland
H5, H7 influenza viruses: where do we go?
Malik Peiris, University of Hongkong
The use of influenza vaccines reduces antimicrobial resistance
Janet McElhaney, Northern Ontario School of Medicine, Canada
Maternal immunization against influenza: benefits to mother and child
Marta Nunes, University of Witwatersrand, RSA

COFFEE BREAK and POSTER TOUR
10:00 - 10:45
10:00 - 10:45

PARALLEL SESSIONS - Clinical impact and diagnostic approaches
10:45 - 12:30
Time
10:45 - 12:30
Location
Omega
Chair: Cheryl Cohen
National Institute for Communicable Diseases, RSA
Co-Chair: Ted van Essen
University Medical Center Utrecht, The Netherlands
1. The clinical impact of routine molecular point-of-care testing for respiratory viruses in hospitalised adults: results of a large pragmatic randomised controlled trial 
Tristan Clark, University of Southampton, UK
2. In- and out-of-hospital mortality associated with seasonal and pandemic influenza and respiratory syncytial virus in South Africa 2009-2013
Cheryl Cohen, National Institute for Communicable Diseases, RSA
3. A Novel Pharmacoeconomic Model to Compare Seasonal Influenza Vaccines in Italian Adults Aged 65 Years and Above
Stefano Capri, Cattaneo-LIUC University, Italy
4. Nasopharyngeal microbial signatures associated with severe influenza in children and in adults
Laurence Josset, Hospices Civils de Lyon, France

PARALLEL SESSIONS - Virus structure and replication
10:45 - 12:30
Time
10:45 - 12:30
Location
Alfa
Chair: Stephen Cusack
EMBL Grenoble, France
Co-Chair: Rocío Coloma
Centro Nacional de Biotecnología, Madrid, Spain
1. Analysis of the Higher Order RNA Structures Present Inside the Influenza A Virus Genome
Bernadeta Dadonaite, University of Oxford, UK
2.High-resolution mapping of Influenza A RNA packaging signals by MIME (Mutational Interference Mapping Experiment)
Maud Contrant, IBMC, France
3. Structural insights into the mechanisms of influenza A virus RNA replication
Haitian Fan, University of Oxford, UK
4. Mechanistic single-molecule analysis of influenza virus replication
Nicole Robb, University of Oxford, UK

Science Policy Interface 1 - All you need to know about influenza viruses
10:45 - 12:30
Time
10:45 - 12:30
Location
Beta
Chair: Ab Osterhaus
RIZ Hannover, Germany
1. All you need to know about influenza viruses
Ab Osterhaus, RIZ Tiho Hannover, Germany
2. Close focus: vaccines and antivirals
Florian Krammer, Mount Sinai School of Medicine, USA
3. How flu viruses travel around the world
Colin Russell, University of Cambridge, UK
4. Who is at risk of flu infections and are these risk groups well-protected? ECDC informs
Pasi Penttinen - ECDC
5. The economic impact of flu: WHO informs
Mohir Ahmedov - WHO Europe

LUNCH / SATELLITE SYMPOSIUM organized by SANOFI PASTEUR
12:30 - 14:00
INFLUENZA: Changing the conversation
INFLUENZA: Changing the conversation
Time
12:30 - 14:00
Location
Omega
Chair: Marc Van Ranst
University Hospitals of Leuven, Belgium
1. Taking influenza seriously: individual and community impact of influenza
Filipe Froes, Respiratory Medicine and Intensive Care Consultant, Lisbon, Portugal
2. Influenza viruses are constantly evolving: the need for Quadrivalent influenza vaccines
Marc Van Ranst, University Hospitals of Leuven, Belgium
3. Developing a QIV: VaxigripTetra® clinical development
Rosalind Hollingsworth, Global Medical Expert Lead, Influenza, Sanofi Pasteur, Swiftwater, USA

PARALLEL SESSIONS - Epidemics and pandemic threats
14:00 - 15:45
Time
14:00 - 15:45
Location
Omega
Chair: Yoshihiro Kawaoka
University of Wisconsin, USA
Co-Chair: Peng Wu
University of Hong Kong, Hong Kong SAR
1. Identification of H1N1 influenza virus survival determinants: amino-acids on the HA protein modulate the stability of viruses in the environment
Thomas Labadie, Institut Pasteur, France
2. Evaluation of potential risk of transmission of Avian Influenza A at the human-animal interface in response to unusual crow die off in Bangladesh
Mahbubur Rahman, Institute of Epidemiology, Disease Control and Research, Bangladesh
3. Outbreak of highly pathogenic avian influenza A virus H5N1 among poultry in Ghana
Ivy Assante, Heinrich-Pette-Institute, Germany
4. Influenza-associated mortality in Yancheng, China, 2011-2015
Qian Xiong, University of Hong Kong, Hong Kong SAR

PARALLEL SESSIONS - Viral factors in pathogenesis
14:00 - 15:45
Time
14:00 - 15:45
Location
Alfa
Chair: Adolfo Garcia-Sastre
Mount Sinai School of Medicine, USA
Co-Chair: Michelle Tate
Hudson Institute of Medical Research, Australia
1. Factors determining the optimum pH stability for pathogenicity and transmissibility of human influenza viruses
Anika Singanayagam, Imperial College London, UK
2. Variable pathogenicity of H7N7 recombinant viruses in chickens, turkeys and ducks
David Scheibner, Friedrich-Loeffler Institut, Germany
3. Avian-origin PB1 Segment of Influenza A Virus Confers a Parallel Selective Advantage towards Virus Adaptation and Pandemic Formation
Yan Zhou, University of Saskatchewan, Canada
4. Functional analysis of the influenza A virus M2 protein interaction with Na,K-ATPase in influenza pneumonia
Jessica Schulze, Robert Koch Institute, Germany

Science Policy Interface 2 - Prevention and treatment of influenza
14:00 - 15:45
Time
14:00 - 15:45
Location
Beta
Chair: Jonathan Van-Tam
University of Nottingham, UK
1. Vaccines: current and novel approaches
Peter Palese, Mount Sinai School of Medicine, USA
2. Effectiveness of seasonal and pandemic influenza vaccines
Jonathan Van-Tam, University of Nottingham, UK
3. Safety of seasonal and pandemic influenza vaccines
Michael McNeil, CDC Immunization Safety Office, USA
4. Antiviral medicines against influenza: current and novel approaches
Lieve Naesens, Rega Institute KU Leuven, Belgium
5. Safety and effectiveness of influenza antivirals
Nicole Bouvier, Mount Sinai School of Medicine, USA

COFFEE BREAK
15:45 - 16:15

PARALLEL SESSIONS - Immunology
16:15 - 18:00
Time
16:15 - 18:00
Location
Omega
Chair: Rory Dylan de Vries
Erasmus MC Rotterdam, The Netherlands
1. First identification of cross-reactive CD8+ T cell immunity across influenza A, B and C viruses
Marios Koutsakos, University of Melbourne, Australia
2. Engaging naive vs. memory B cells in humans: Lessons from H5N1 vaccination
Ali Ellebedy, Emory University, USA
3. Extra-epitopic amino acids influence recognition of the 2009 H1N1 pandemic influenza A virus by CD8+ T cells specific for the conserved M158-66 epitope
Carolien van de Sandt, Erasumus MC Rotterdam, The Netherlands
4. Constitutive TRIM22 expression confers intrinsic antiviral immunity in the respiratory tract
Edward Hutchinson, University of Glasgow, UK

PARALLEL SESSIONS - Mathematical modelling
16:15 - 18:00
Time
16:15 - 18:00
Location
Alfa
Chair: Colin Russell
Cambridge University, UK
Co-Chair: Katelyn Gostic
University of California, USA
1. Population dynamics constrain immune escape in human influenza A
Dylan Morris, Princeton University, USA
2.Estimates of Annual and Average Global Seasonal Influenza-associated Respiratory Mortality form 1999-2015 
Angela Iuliano, Centers for Disease Control and Prevention, USA
3. Failing to account for pre-existing immunity against influenza strains leads to an underestimation of influenza vaccine efficacy
Pascal Crépey, Ecole des Hautes Etudes en Santé Publique, France
4. Should we expect broadly protective immunity and childhood hemagglutinin imprinting to impact seasonal influenza epidemiology? 
Katelyn Gostic, University of California, USA

Science Policy Interface 3 - Addressing influenza in practice: who's involved?
16:15 - 18:00
Time
16:15 - 18:00
Location
Beta
Chair: Susanne Herold
University of Giessen, Germany
1. Family doctors: our trusted advisors
Ted van Essen, general practitioner, The Netherlands
2. Protecting healthcare workers and patients in hospital settings
Roman Prymula, University Hospital Hradec Kralove, Czech Republic
3. Nurses and midwives: in the forefront in the fight against flu
Agita Melbārde Kemlere, Latvian Nurses Association
4. The new role of pharmacists in flu prevention
Isabel Jacinto, National Association of Pharmacies, Portugal
5. Respiratory physicians tackling influenza
Susanne Herold, University of Giessen, Germany

PRIVATE SATELLITE SYMPOSIUM
18:00 - 19:30
Time
18:00 - 19:30
Location
Omega

 

08:00
08:30
09:00
09:30
10:00
10:30
11:00
11:30
12:00
12:30
13:00
13:30
14:00
14:30
15:00
15:30
16:00
16:30
17:00
17:30
18:00
18:30
19:00
19:30
20:00
20:30
21:00
21:30
22:00
12 SEPTEMBER 2017
12 SEPTEMBER 2017
SATELLITE SYMPOSIUM: COMPANY LECTURES
08:00 - 09:00
08:00 - 09:00
Chair: Ted van Essen
University Medical Center Utrecht, The Netherlands
Location
Omega
(8:00 - 8:20) Influenza Hub: Raising awareness about influenza prevention by using social media and innovative engagement techniques
Philip Weiss, ZN Consulting, and Bram Palache, FluPal Consultancy B.V.
(8:20 - 8:40) Treatment of Influenza and RSV – Janssen’s Pipeline in Respiratory Infections
Jim Witek, Global Franchise Medical Leader, Respiratory Infectious Diseases, Janssen
(8:40 - 9:00) Update on the Clinical Development of Plant-Made Quadrivalent Influenza VLP Vaccine
Brian J. Ward, Medical Officer for Medicago

PLENARY SESSION - keynote lectures
09:00 - 10:00
09:00 - 10:00
Chair: Marco Goeijenbier
Harbour Hospital Rotterdam, The Netherlands
Location
Omega
Clinical management of influenza: where do we go?
Jonathan Van-Tam, University of Nottingham, UK
Protective and pathological roles of coagulation proteases and PARs in influenza infection
Nigel Mackman, University of North Carolina at Chapel Hill

COFFEE BREAK and POSTER TOUR
10:00 - 10:45
10:00 - 10:45

PARALLEL SESSIONS - Antivirals and resistance / Monoclonal antibody therapies
10:45 - 12:30
Time
10:45 - 12:30
Chair: Elena Govorkova
St. Jude Children's Research Hospital, USA
Co-Chair: Florian Krammer
Mount Sinai School of Medicine, USA
Location
Omega
1. Mechanisms of protection of monoclonal anti-influenza B neuraminidase IgG, IgM and IgA antibodies in a murine challenge model
Veronika Chromikova, Mount Sinai School of Medicine, USA
2. A Host-Directed Antiviral Approach for Treatment of Influenza Virus Infections
Kelly Warfield, Emergent Biosolutions, USA
3. Impact of in-hospital neuraminidase inhibitor treatment on length of stay: an Individual Participant Data Meta-analysis
Sudhir Venkatesan, University of Nottingham, UK
4. Resistance analyses in subjects treated with pimodivir (jnj-63623872): results from the phase 2b topaz trial in acute uncomplicated seasonal influenza
Johan Vingerhoets, Janssen, Belgium

PARALLEL SESSIONS - Animal flu-ecology and epidemiology of animal influenza
10:45 - 12:30
Time
10:45 - 12:30
Chair: Gavin Smith
Duke-NUS, Singapore
Co-Chair: Josanne Verhagen
Linnaeus University Växjö, Sweden
Location
Alfa
1. Swarm incursions during winter 2016/17 of multiple reassortants of highly pathogenic avian H5N8 influenza strains causing the largest epizootic in birds ever recorded in Germany
Martin Beer, Friedrich Löffler Institut, Germany
2. Circulation, prevalence and genetic analyses of wild bird avian influenza viruses in a key active surveillance site in Eurasia: 2010-2017
Nicola Lewis, APHA Virology, UK
3. Circulation of low and highly pathogenic avian influenza A viruses among wild and domestic birds in Ukraine
Denys Muzyka, National Scientific Center Institute of Experimental and Clinical Veterinary Medicine, Ukraine
4. Mobile poultry vendors in Bangladesh: practices and movement patterns
Ausraful Islam, ICDDR, Bangladesh

Science Policy Interface 4 - Implementation of vaccination policies: success stories and hurdles
10:45 - 12:30
Time
10:45 - 12:30
Chair: Peter Openshaw
Imperial College London, UK
Location
Beta
1. How does NHS England manage to achieve one of the highest seasonal Influenza vaccination rates in Europe?
George Kassianos, Immunisation Lead for the Royal College of General Practitioners, UK
2. Influenza vaccination in Mexico
Jose Angel Cordova Villalobos, Mexico, former Minister of Health (2006 - 2011)
3. The role of ‘experts’ in guiding policy: the immunologist’s perspective
Peter Openshaw, Imperial College London, UK
4. A journalist's opinion on vaccination policies and the role of scientists
Debora McKenzie, New Scientist Magazine
5. The socio-economic burdens of seasonal influenza
Alexander Khoury, Harvard Chan School of Public Health, US

LUNCH and SATELLITE SYMPOSIUM organized by Seqirus
12:30 - 14:00
Seasonal Influenza in Older Adults: Addressing the challenges and understanding immunization options
Seasonal Influenza in Older Adults: Addressing the challenges and understanding immunization options
Time
12:30 - 14:00
Location
Omega
Dr. George Kassianos
President British Global & Travel Health Association and National Immunisation Lead Royal College of General Practitioners
Dr. Paul Van Buynder
Professor, Griffith University and Chairman, Immunisation Coalition
Dr. Adolfo García-Sastre
Professor, Icahn School of Medicine at Mount Sinai and Director, Global Health and Emerging Pathogens Institute
Prof. Marco Barbieri
Honorary Research Fellow, Centre for Health Economics, University of York

PARALLEL SESSIONS - Vaccines: current and novel approaches
14:00 - 15:45
Time
14:00 - 15:45
Chair: Ali Ellebedy
Emory University, USA
Location
Omega
1. Nucleoside-modified mRNA vaccination induces influenza virus hemagglutinin stalk-specific antibody responses
Norbert Pardi, University of Pennsylvania, USA
2. Adjuvanted mini-HA induces broadly neutralizing antibodies in pre-exposed non-human primates which protect mice from lethal influenza challenge
Börries Brandenburg, Janssen, The Netherlands
3. Influenza virus hemagglutinin stalk-specific antibodies in human sera measured by ELISA correlate with in vivo protection in a mouse serum transfer model
Raffael Nachbagauer, Mount Sinai School of Medicine, USA
4. Pre-existing orthopoxvirus-specific immunity interferes with t cell responses induced by vaccination with recombinant modified vaccinia virus ankara in mice
Rory de Vries, Erasmus MC Rotterdam, The Netherlands

PARALLEL SESSIONS - Genetics and evolution of virus and host
14:00 - 15:45
Time
14:00 - 15:45
Chair: Ron Fouchier
Erasmus MC Rotterdam, The Netherlands
Co-Chair: Craig Thompson
University of Oxford, UK
Location
Alfa
1. Avian influenza A/H10N7 virus outbreak in seals: identification and characterization of mutations and associated phenotypes driving airborne transmission between ferrets
Sander Herfst, Erasmus MC, The Netherlands
2. Characterization of a newly emerged variant of H7N9 virus containing a polybasic motif in the hemagglutinin protein
Honglin Chen, University of Hong Kong, Hong Kong SAR
3. Polymerase enhancing substitutions that arise during infection with highly pathogenic avian H5N1 influenza in humans
Dirk Eggink, Academic Medical Center Amsterdam, The Netherlands
4. Influenza virus quasispecies characterization of serial upper and lower respiratory tract samples from mechanically ventilated patients
Björn Koel, Academic Medical Center Amsterdam, The Netherlands

Science Policy Interface 5 - Influenza preparedness: what can we learn from other virus outbreaks?
14:00 - 15:45
Time
14:00 - 15:45
Chair: Marc Van Ranst
University of Leuven, Belgium
Location
Beta
1. Ebola: what went wrong and where do we go now?
Guido van der Groen, Prof. Em. Institute for Tropical Medicine in Antwerp, Belgium
2. Zika virus as a global public health emergency
Herve Zeller, head of disease programme for Emerging and vector-borne diseases, ECDC
3. How to successfully prevent a major disease outbreak: from SARS to MERS
Ab Osterhaus, RIZ Tiho Hannover, Germany
4. The H1N1 health crisis: how did we cope and are we prepared for a new outbreak?
Marc Van Ranst, University of Leuven, Belgium
5. Revised pandemic preparedness plans and global update on PIP Framework
Wenqing Zhang, Global Influenza Programme, World Health Organization, Switzerland

COFFEE BREAK
15:45 - 16:15

PARALLEL SESSIONS - Evaluation of vaccine safety and effectiveness
16:15 - 18:00
Time
16:15 - 18:00
Chair: Maryna Eichelberger
Food and Drug Administration, USA
Co-Chair: Katja Höschler
Public Health England, UK
Location
Omega
1. Efficacy immunogenicity and safety study of a 0.5 ml dose of a quadrivalent inactivated influenza vaccine in children from 6 to 35 months
Stephanie Pepin, Sanofi Pasteur, France
2. Assessment of the effect of repeated vaccination on current season influenza vaccine effectiveness (IVE) in patients 60 years old or over, seasons 2013-2014 to 2015-2016 in the Valencia Region (Spain)
Javier-Díez Domingo, FISABIO, Spain
3. A new hospital surveillance system in norway for severe influenza in children 
Håkon Bøås, Institute of Public Health, Norway
4. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine co-administered with a 23-valent pneumococcal polysaccharide vaccine, versus separate administration, in ≥50-year-old adults: results from phase III, randomized, non-inferiority trial
Geert Leroux-Roels, University of Ghent, Belgium

PARALLEL SESSIONS - Risk management and mitigation of epidemic and pandemic threats
16:15 - 18:00
Time
16:15 - 18:00
Chair: Marie-Paule Kieny
World Health Organization
Co-Chair: Irina Isakova-Sivak
Institute of Experimental Medicine Saint Petersburg, Russia
Location
Alfa
1. Effect of a reinforced hospital campaign for seasonal influenza vaccination of healthcare workers 2016-2017 on nosocomial outbreaks in the University Hospital of Lyon, France
Bruno Lina, University of Lyon, France
2. Partnership for Influenza Vaccine Introduction: early progress in catalyzing influenza vaccine use in low and middle-income countries
Malembe Ebama, Centers for Disease Control and Prevention, USA
3. Outbreaks of highly pathogenic avian influenza A(H5N5) and A(H5N8) virus infection in birds: National risk assessments and protective measures for humans in 22 EU/EEA countries, 2016/17 
Cornelia Adlhoch, European Centre for Disease Prevention and Control, Sweden
4. 2016/17 Seasonal Influenza Vaccine Uptake by Medical Students in the UK
Rachel Groome, University of Nottingham, UK

Science Policy Interface 6 - Reaching out to people at risk
16:15 - 18:00
Time
16:15 - 18:00
Chair: Litjen Tan
Immunization Action Coalition, USA
Location
Beta
1. Should children be vaccinated against influenza?
Adam Finn, University of Bristol, UK and president ESPID
2. Should travellers be vaccinated against flu?
Marco Goeijenbier, Harbour Hospital Rotterdam, The Netherlands
3. Protecting diabetes patients against flu
Perry van Genderen, Harbour Hospital Rotterdam, The Netherlands
4. Reaching out to the elderly: why and how
Janet McElhaney, Northern Ontario School of Medicine, Canada
5. Vaccinating pregnant women against influenza
Erin Sparrow (WHO)
6. The benefits of a universal vaccination recommendation: the US case
Litjen Tan, Immunization Action Coalition, USA

SATELLITE SYMPOSIUM organized by MUGAS Foundation
18:00 - 19:30
Next generation influenza vaccines: the future of influenza immunization
Next generation influenza vaccines: the future of influenza immunization
Time
18:00 - 19:30
Chair: Ab Osterhaus
ESWI chair and MUGAS co-founder
Location
Omega
1. The need for improved influenza vaccines and adjuvants
Ab Osterhaus, ESWI chair and MUGAS co-founder
2. Molecular basis of strain variation
Ron Fouchier, Erasmus MC Rotterdam, The Netherlands
3. Pre-emptive vaccine updates and immunity management
Derek Smith, Cambridge University, UK
4. Mammalian Cell Culture and the Evolution of the Influenza Vaccine System
Ethan C. Settembre, Seqirus, Cambridge, MA, USA
5. The plant-based Proficia™ technology, a rapid and efficient platform for the production of influenza VLP vaccines
Nathalie Charland, Senior Director, Scientific & Medical Affairs for Medicago
6. Influenza adjuvanted surface low-dose Grippol® Quadrivalent vaccine immunogenicity, safety and efficacy
Marina Abramova, Vice President, NPO Petrovax Pharm
7. The revolution in influenza vaccine manufacturing: The B.E.S.T. platform used to produce Flublok ®
Manon Cox, President and CEO, Protein Sciences

Farewell Dinner
20:00 - 22:00
Time
20:00 - 22:00
Location
Latvia Society House

 

08:00
08:30
09:00
09:30
10:00
10:30
11:00
11:30
12:00
12:30
13:00
13:30
14:00
14:30
13 SEPTEMBER 2017
13 SEPTEMBER 2017
YOUNG SCIENTISTS PLENARY SESSION
08:00 - 09:15
08:00 - 09:15
Chair: Ed Hutchinson
University of Glasgow, UK
Co-Chair: Claude Hannoun
Institut Pasteur Paris, France
Location
Omega

SPEAKERS:
1. Debby van Riel (ESWI Best Body of Work award winner 2017)
2. Matthew S. Miller (Best Oral Presentation ESWI 2014)
3. Steven F. Baker (Best Poster Presentation ESWI 2014)
4. Karen Laurie (Award Winner Orthomyxovirus Research Conference 2015)
5. Jason Long (Award Winner Orthomyxovirus Research Conference 2015)

COFFEE BREAK and POSTER TOUR
09:15 - 10:00
09:15 - 10:00

PARALLEL SESSIONS - Maternal and childhood immunization
10:00 - 11:45
Time
10:00 - 11:45
Chair: Terho Heikkinen
University of Turku, Finland
Co-Chair: Marta Nunes
University of Witwatersrand, RSA
Location
Omega
1. Seroprevalence of seasonal influenza virus infection among unvaccinated pregnant women in Bangladesh, 2013-2014
Zubair Akhtar, ICDDR, Bangladesh
2. Influenza A virus infection during pregnancy: high progesterone levels during pregnancy increase mortality in pregnant influenza infected mice by impairing the anti-viral immune response
Alexandra Hierweger, University Medical Center Hamburg-Eppendorf, Germany
3. A randomised controlled trial to increase influenza vaccine uptake in children aged from 6 to 24 months
Karene Yeung, the Chinese University of Hong Kong, Hong Kong SAR
4. Assessing direct and indirect effects of pediatric influenza vaccination in Germany using individual-based simulations – Epidemiological considerations
Ruprecht Schmidt-Ott, GlaxoSmithKline, Germany

PARALLEL SESSIONS - Host factors in pathogenesis
10:00 - 11:45
Time
10:00 - 11:45
Chair: Gülsah Gabriel
Heinrich Pette Institute Hamburg, Germany
Co-Chair: Ivan Marazzi
Mount Sinai School of Medicine, USA
Location
Alfa
1. Emergence of Highly Virulent H1N1 Influenza Virus Strains in Allogenically Pregnant Mice
Stephanie Bertram, Heinrich Pette Institute, Germany
2. SMARCA2-regulated host cell factors are required for MxA restriction of influenza A viruses
Alexandra Dudek, Institute of Virology Freiburg, Germany
3. Resistance to influenza A infections in mice carrying deletions in host protease genes
Klaus Schughart, Helmholtz Centre for Infection Research, Germany
4. The role of obesity in the generation of influenza virus quasispecies
Kirsty Short, University of Queensland, Australia

Science Policy Interface 7 - Influenza prevention in developing countries: a global responsibility
10:00 - 11:45
Time
10:00 - 11:45
Chair: Malik Peiris
University of Hong Kong
Location
Beta
1. The role of developing countries in seasonal and avian influenza
Malik Peiris, University of Hong Kong
2. Global access to influenza vaccines for LMIC - challenges and opportunities
Niteen Wairagkar, Bill&Melinda Gates Foundation
3. Logistical challenges in low income countries
Mark McCaul, Supply Chain Officer at Médecins Sans Frontières
4. Can we prevent severe outcomes through influenza vaccination?
Cheryl Cohen, National Institute for Communicable Diseases, RSA

COFFEE BREAK
11:45 - 12:15

PLENARY SESSION - Late Breakers and Closing Ceremony
12:15 - 13:45
Time
12:15 - 13:45
Chair: Sylvie van der Werf
Institut Pasteur Paris, France
Co-Chair: Susanne Herold
University of Giessen, Germany
Location
Omega
1. Efficacy and Safety of Oseltamivir in Children: Systematic Review and Meta-analysis of Randomized Controlled Trials
Arnold S Monto, University of Michigan School of Public Health, United States of America
2. Cap-Dependent Endonuclease Inhibitor S-033188 for the Treatment of Influenza in Otherwise Healthy Adolescents and Adults with Seasonal Influenza
Frederick Hayden, University of Virginia School of Medicine, Charlottesville, Virginia, USA
3. The OPAL Trial: A Placebo-controlled Trial Studying Pimodivir (Formerly JNJ-63623872 or VX-787) plus Oseltamivir vs. Placebo plus Oseltamivir in Adult and Elderly Hospitalized Patients with Influenza A Infection
Lorant Leopold, Janssen Research & Development, LLC, Titusville, NJ, USA
4. Targeting the pro-viral host factor, focal adhesion kinase (FAK), limits influenza A virus infections and NFkB regulated pro-inflammatory responses in vivo and in vitro
Husni Elbahesh, Department of Microbiology, Immunology and Biochemistry, University of Tennessee Health Science Center, Memphis, Tennessee, United States of America

LUNCH
13:45 - 14:30
Time
13:45 - 14:30